US Bancorp’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,988
| Closed | -$360K | – | 4304 |
|
|
2025
Q4 | $360K | Sell |
4,988
-348
| -7% | -$22.5K | ﹤0.01% | 1716 |
|
|
2025
Q3 | $232K | Buy |
5,336
+41
| +0.8% | +$1.66K | ﹤0.01% | 1928 |
|
|
2025
Q2 | $150K | Sell |
5,295
-173
| -3% | -$5.16K | ﹤0.01% | 2208 |
|
|
2025
Q1 | $161K | Sell |
5,468
-1,100
| -17% | -$34.3K | ﹤0.01% | 2133 |
|
|
2024
Q4 | $191K | Buy |
6,568
+1,324
| +25% | +$55.3K | ﹤0.01% | 2051 |
|
|
2024
Q3 | $241K | Sell |
5,244
-53,154
| -91% | -$2.31M | ﹤0.01% | 1938 |
|
|
2024
Q2 | $2.39M | Sell |
58,398
-3,706
| -6% | -$106K | ﹤0.01% | 781 |
|
|
2024
Q1 | $1.58M | Buy |
62,104
+140
| +0.2% | +$2.19K | ﹤0.01% | 931 |
|
|
2023
Q4 | $561K | Buy |
61,964
+1,497
| +2% | +$10K | ﹤0.01% | 1423 |
|
|
2023
Q3 | $386K | Buy |
60,467
+1,940
| +3% | +$16.7K | ﹤0.01% | 1497 |
|
|
2023
Q2 | $649K | Buy |
58,527
+1,305
| +2% | +$16.4K | ﹤0.01% | 1261 |
|
|
2023
Q1 | $878K | Sell |
57,222
-19,560
| -25% | -$430K | ﹤0.01% | 1138 |
|
|
2022
Q4 | $1.7M | Buy |
76,782
+1,320
| +2% | +$19.7K | ﹤0.01% | 864 |
|
|
2022
Q3 | $1.23M | Sell |
75,462
-50,370
| -40% | -$964K | ﹤0.01% | 969 |
|
|
2022
Q2 | $1.83M | Buy |
125,832
+56,865
| +82% | +$846K | ﹤0.01% | 848 |
|
|
2022
Q1 | $1.27M | Sell |
68,967
-69,041
| -50% | -$1.17M | ﹤0.01% | 1074 |
|
|
2021
Q4 | $3.28M | Sell |
138,008
-118,260
| -46% | -$2.82M | 0.01% | 723 |
|
|
2021
Q3 | $6.31M | Buy |
256,268
+254,868
| +18,205% | +$5.54M | 0.01% | 515 |
|
|
2021
Q2 | $35K | Hold |
1,400
| – | – | ﹤0.01% | 2844 |
|
|
2021
Q1 | $31K | Buy |
+1,400
| New | +$34.3K | ﹤0.01% | 2819 |
|
Other funds holding RNAM
US Bancorp's RNAM Position: Q1 2026 in Review
US Bancorp sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 4,988 shares — an estimated $360K sold.
US Bancorp first reported a position in RNAM in Q1 2021 and held it in 20 quarters. The position peaked at $6.31M in Q3 2021. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- US Bancorp reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- US Bancorp sold 4,988 Avidity Biosciences shares in Q1 2026, an estimated $360K.
- US Bancorp first reported a position in Avidity Biosciences in Q1 2021 and held it in 20 quarters.
- US Bancorp's Avidity Biosciences position peaked at $6.31M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.